|
Reference | Sample size | Animal type | Method of SCI | Treatment groups | Route & timing of curcumin administration | Pathological findings | Outcomes/results |
|
Şahin Kavakli et al. [26] | 24 | Wistar rats | Weight drop | After SCI: curcumin, methylprednisolone, or control | Orally; continuously until sacrificing | — | Higher SOD levels in curcumin group versus other two groups; lower MDA levels in curcumin & methylprednisolone groups versus control |
|
Sanli et al. [27] | 40 | Wistar rats | Weight drop | No SCI, SCI alone, SCI/DMSO, SCI/curcumin/DMSO, and SCI/methylprednisolone | Single intraperitoneal dose directly after SCI | No difference in caliber of myelinated axons; less mitochondrial trauma in curcumin, methylprednisolone, and DMSO groups | Decreased lipid peroxidation and MDA levels in curcumin group; curcumin, methylprednisolone, and DMSO groups with improved neurological/functional tests |
|
Liu et al. [28] | 36 | New Zealand rabbits | Transient (30 min) abdominal aortic occlusion | Sham SCI, SCI only, and SCI/curcumin | Single venous injection 10 minutes prior to SCI | Greater histologically normal neurons & fewer apoptotic cells in curcumin group | Improved neurological (motor) function in curcumin group |
|
Yao et al. [29] | 8 | — | Various | Meta-analysis of 8 studies of curcumin versus control | Various | — | Curcumin-treated animals with lesser MDA levels and improved neuromotor functioning with potential dose response |
|